Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03469271 · ClinicalTrials.gov registry record · Phase 4
Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
NCT03469271: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT03469271 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03469271, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
Study Summary
This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).
Interventions
- DRUG Oral Placebo
- DRUG 1,25 (OH)2 D3
- OTHER Inspiratory isometric resistance training
- OTHER Sham Inspiratory Isometric Resistance Training
- DEVICE Threshold Inspiratory Muscle Trainer (IMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-05-25 |
| Est. Completion | 2020-05-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03469271
The ClinicalTrials.gov registry entry for NCT03469271 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oral Placebo is the first listed.
NCT03469271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03469271 about?
NCT03469271 is a clinical study titled "Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients". This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).
What is the current status of trial NCT03469271?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2018-05-25. Estimated completion is 2020-05-21.
What interventions are being tested in trial NCT03469271?
The interventions under investigation include: Oral Placebo (DRUG), 1,25 (OH)2 D3 (DRUG), Inspiratory isometric resistance training (OTHER), Sham Inspiratory Isometric Resistance Training (OTHER), Threshold Inspiratory Muscle Trainer (IMT) (DEVICE).
Who is sponsoring clinical trial NCT03469271?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.